Annals of Hematology

, Volume 86, Issue 3, pp 159–172

Towards a new age in the treatment of multiple myeloma

  • Francesco A. Piazza
  • Carmela Gurrieri
  • Livio Trentin
  • Gianpietro Semenzato
Review Article

DOI: 10.1007/s00277-006-0239-5

Cite this article as:
Piazza, F.A., Gurrieri, C., Trentin, L. et al. Ann Hematol (2007) 86: 159. doi:10.1007/s00277-006-0239-5

Abstract

Multiple myeloma (MM) is an incurable disease characterized by the proliferation of end-stage B lymphocytes (plasma cells, PCs). As a consequence of myeloma growth in the bone marrow, a number of signaling pathways are activated that trigger malignant PC proliferation, escape from apoptosis, migration, and invasion. Thanks to new insights into the molecular pathogenesis of MM, novel approaches aimed at targeting these abnormally activated cascades have recently been developed and others are under study. These strategies include the inhibition of membrane receptor tyrosine kinases, inhibition of the proteasome/aggresome machinery, inhibition of histone deacetylases, inhibition of farnesyltransferases, targeting of molecular chaperones, and others. We will herein review and discuss these novel biological approaches with particular emphasis on those based on biochemical pathways which drive cell signaling. By providing the rationale for innovative therapeutic strategies, the above mechanisms represent targets for new compounds being tested in the management of this disease.

Keywords

Multiple myeloma Microenvironment Drug-resistance Biological therapy Cell signaling 

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Francesco A. Piazza
    • 1
    • 2
  • Carmela Gurrieri
    • 1
    • 2
  • Livio Trentin
    • 1
    • 2
  • Gianpietro Semenzato
    • 1
    • 2
  1. 1.Department of Clinical and Experimental MedicineUniversity of PadovaPadovaItaly
  2. 2.Venetian Institute of Molecular Medicine, Haematological Malignancies UnitPadua University School of MedicinePadovaItaly

Personalised recommendations